OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS. RESULTS OF LYMA‐101 TRIAL, A LYSA GROUP STUDY
Saved in:
Published in | Hematological oncology Vol. 37; no. S2; pp. 44 - 45 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Chichester
Wiley Subscription Services, Inc
01.06.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
ISSN: | 0278-0232 1099-1069 |
---|---|
DOI: | 10.1002/hon.14_2629 |